Letter

Response to 'Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months'

Miguel A Gonzalez-Gay1†, Carlos Gonzalez-Juanatey2, Jose A Miranda-Filloy3, Javier Martin4, Maria T Garcia-Unzueta5 and Javier Llorca6,7*†

Author Affiliations

1 Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida de Valdecilla s/n, 39008-Santander, IFIMAV, Santander, Spain

2 Division of Cardiology, Hospital Xeral-Calde, c) Dr. Ocha s/n, 27004-Lugo, Spain

3 Division of Rheumatology, Hospital Xeral-Calde, c) Dr. Ocha s/n, 27004-Lugo, Spain

4 Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas (C.S.I.C.), Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento, s/n, 18100 Armilla, Granada, Spain

5 Endocrinology Research Unit, Hospital Universitario Marqués de Valdecilla, Avenida de Valdecilla s/n, 39008-Santander, IFIMAV, Santander, Spain

6 Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Avda. Herrera Oria s/n. 39011-Santander, Spain

7 CIBER Epidemiología y Salud Pública (CIBERESP), IFIMAV, Spain

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13:404 doi:10.1186/ar3301

Published: 27 April 2011

First paragraph (this article has no abstract)

We read with great interest the study by Engvall and colleagues [1] in a recent issue of Arthritis Research & Therapy. The study showed that anti-tumor necrosis factor-alpha (anti-TNF-α) infliximab therapy is associated with an increase of body fat mass in early rheumatoid arthritis (RA) independently of changes in disease activity and levels of leptin and adiponectin.